14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $4.18 $5.34 Wednesday, 24th Apr 2024 BCRX stock ended at $4.21. This is 3.88% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 5.74% from a day low at $4.18 to a day high of $4.42.
90 days $4.18 $6.35
52 weeks $4.18 $9.07

Historical BioCryst Pharmaceuticals prices

Date Open High Low Close Volume
Dec 04, 2020 $5.85 $6.25 $5.75 $6.10 39 891 223
Dec 03, 2020 $5.14 $5.19 $4.90 $5.14 9 060 226
Dec 02, 2020 $4.82 $5.17 $4.74 $5.04 6 421 285
Dec 01, 2020 $5.16 $5.17 $4.78 $4.87 4 923 321
Nov 30, 2020 $5.18 $5.29 $4.83 $5.11 8 249 701
Nov 27, 2020 $4.81 $5.13 $4.80 $5.13 3 789 582
Nov 25, 2020 $4.74 $4.78 $4.59 $4.76 4 466 372
Nov 24, 2020 $4.52 $4.84 $4.52 $4.66 7 610 476
Nov 23, 2020 $4.38 $4.48 $4.26 $4.40 4 194 509
Nov 20, 2020 $4.15 $4.37 $4.12 $4.33 3 638 486
Nov 19, 2020 $4.28 $4.41 $4.06 $4.17 4 919 618
Nov 18, 2020 $4.57 $4.57 $4.27 $4.28 4 633 246
Nov 17, 2020 $4.39 $4.59 $4.33 $4.58 3 492 209
Nov 16, 2020 $4.39 $4.47 $4.25 $4.45 3 909 939
Nov 13, 2020 $4.33 $4.47 $4.30 $4.41 2 981 191
Nov 12, 2020 $4.21 $4.46 $4.19 $4.25 4 953 796
Nov 11, 2020 $4.08 $4.28 $4.08 $4.26 3 663 195
Nov 10, 2020 $3.85 $4.10 $3.82 $4.08 5 095 372
Nov 09, 2020 $3.98 $4.07 $3.78 $3.88 6 403 931
Nov 06, 2020 $4.30 $4.30 $4.01 $4.08 3 755 143
Nov 05, 2020 $4.30 $4.37 $3.92 $4.24 5 967 302
Nov 04, 2020 $3.90 $4.30 $3.88 $4.27 5 902 654
Nov 03, 2020 $3.80 $4.02 $3.74 $3.95 4 648 358
Nov 02, 2020 $3.82 $3.88 $3.71 $3.85 2 986 879
Oct 30, 2020 $3.77 $3.84 $3.70 $3.82 4 266 685
Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT